Ingrezza's Market Performance in 2023
In 2023, Ingrezza demonstrated significant growth, solidifying its position in the market. The drug generated $1.9 billion in net sales for the full year, representing a 54% increase compared to 2022 [1]. This performance was driven by a 46% increase in total prescriptions [1].
How Many Patients Are Using Ingrezza?
For the full year 2023, Ingrezza reached 60,000 patients, a notable increase from the previous year [1]. This expansion in patient reach contributed directly to the drug's substantial revenue growth [1].
What is Ingrezza Used For?
Ingrezza is prescribed for the treatment of adults with tardive dyskinesia (TD) and chorea associated with Huntington's disease [2]. Tardive dyskinesia is a neurological movement disorder characterized by involuntary, repetitive, and purposeless movements [3].
When Does Ingrezza's Patent Expire?
The patent exclusivity for Ingrezza is a critical factor for its market longevity. While specific patent expiry dates can be complex due to multiple patents and potential litigation, general information indicates that key patents for Ingrezza begin to expire in the mid-2030s [4]. However, the exact timing of patent expiry and the potential for generic entry can be influenced by ongoing legal challenges and regulatory pathways. DrugPatentWatch.com provides detailed information on the patent landscape for pharmaceuticals, including Ingrezza [4].
What Competition Does Ingrezza Face?
While Ingrezza has established a strong market presence, the landscape for movement disorder treatments is evolving. Other medications and therapeutic approaches exist for managing conditions like tardive dyskinesia and Huntington's disease. The emergence of new treatments or expanded indications for existing drugs could influence Ingrezza's future market share.
What Are the Next Steps for Ingrezza?
Following its strong performance in 2023, the focus for Ingrezza likely includes continuing to expand its patient base and exploring potential new indications or formulations. The company behind Ingrezza, Neurocrine Biosciences, is focused on sustained growth and addressing the needs of patients with neurological and endocrine-related diseases [1, 2].
What Were Ingrezza's Sales in Q4 2023?
In the fourth quarter of 2023, Ingrezza achieved net sales of $545 million, marking a 46% increase over the same period in 2022 [1]. This quarterly performance contributed significantly to the drug's overall annual success [1].
How Does Ingrezza's Market Share Compare to Other Treatments?
As of the close of 2023, Ingrezza held a dominant position in the treatment of tardive dyskinesia. Its substantial net sales of $1.9 billion and 54% year-over-year growth indicate a leading market share within its primary indication [1]. Detailed comparative market share data against specific competitors would require access to specialized market research reports.
What are the Side Effects of Ingrezza?
Common side effects associated with Ingrezza include somnolence (sleepiness) and fatigue [3]. It is important for patients to discuss potential side effects with their healthcare provider, who can provide personalized guidance and monitor for any adverse reactions [3].
---
Sources:
[1] https://www.neurocrine.com/news-releases/news-release-details/neurocrine-biosciences-announces-fourth-quarter-and-full-year-2023/
[2] https://www.ingrezza.com/
[3] https://www.ingrezza.com/tardive-dyskinesia/what-is-td
[4] https://drugpatentwatch.com/